ストックスクリーナーアプリを入手
8.87
0.11%
-0.01
アフターアワーズ：
8.87
Myriad Genetics Inc (MYGN) 最新ニュース
Cancer Biomarkers Market Set to Witness Significant Growth - openPR.com
Is Myriad Genetics Stock Worth Holding in Your Portfolio Now? - MSN
Myriad Genetics stock hits 52-week low at $9.36 amid challenges By Investing.com - Investing.com South Africa
Myriad Genetics stock hits 52-week low at $9.36 amid challenges - Investing.com Australia
Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Press Release Service: United States Molecular Diagnostics Market Forecast Report and Company Analysis 2025-2033 Featuring F Hoffmann-la Roche, Illumina, Hologic, Agilent, Qiagen, Myriad Genetics, Abbott, Danaher, BD & CoResearchAndMarkets.co - CRISPR Medicine News
Trend Tracker for (MYGN) - Stock Traders Daily
Global Preventive Healthcare Technologies And Services Market - openPR
The Future of Genetic Testing: Industry Growth, Trends & Key - openPR
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31% - Simply Wall St
Myriad Genetics upgraded at Piper Sandler on balanced risk reward setup - MSN
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade - Benzinga
Myriad Genetics (MYGN) Stock Jumps on Analyst Upgrade - GuruFocus.com
Myriad Genetics Shares Rise After Upgrade From Piper Sandler -March 12, 2025 at 02:53 pm EDT - Marketscreener.com
Myriad Genetics stock upgraded at Piper Sandler (MYGN:NASDAQ) - Seeking Alpha
Why Are Myriad Genetics (MYGN) Shares Soaring Today - Yahoo Finance
This HubSpot Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Medical Equipment Stock Jumps on Upgrade - Schaeffers Research
Buy Rating on Myriad Genetics: Strategic Changes and Growth Potential Amid Challenges - TipRanks
Piper Sandler upgrades Myriad to 'overweight' on CEO change - TradingView
Piper Sandler Upgrades Myriad Genetics to Overweight From Neutral, Adjusts Price Target to $12.50 From $11.50 - Marketscreener.com
Myriad Genetics upgraded to Overweight from Neutral at Piper Sandler - TipRanks
Morgan Stanley cuts Myriad Genetics stock target to $16 from $21 - Investing.com Canada
(MYGN) On The My Stocks Page - Stock Traders Daily
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance
Myriad Genetics at Leerink Global Healthcare Conference: Strategic Growth Amid Challenges - Investing.com Canada
Myriad Genetics stock hits 52-week low at $9.74 amid challenges - Investing.com Canada
Myriad Genetics stock hits 52-week low at $9.74 amid challenges By Investing.com - Investing.com South Africa
Myriad Genetics, Inc. to Host Earnings Call - ACCESS Newswire
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Cancer Biomarkers Research Report 2024: Global Market Projected to Soar to USD 62.14 Billion by 2034, Driven by Technological Advancements and Increasing Demand for Early Detection - GlobeNewswire Inc.
Piper Sandler Lowers Myriad Genetics (NASDAQ:MYGN) Price Target to $11.50 - Defense World
US$19.13: That's What Analysts Think Myriad Genetics, Inc. (NASDAQ:MYGN) Is Worth After Its Latest Results - Yahoo Finance
Analyst Expectations For Myriad Genetics's FutureMyriad Genetics (NASDAQ:MYGN) - Benzinga
Myriad Genetics Faces Financial Uncertainty Amid Potential Tax Law Changes - TipRanks
Myriad Genetics (NASDAQ:MYGN) Announces Quarterly Earnings Results - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Lowered to Hold Rating by StockNews.com - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Sets New 12-Month Low on Disappointing Earnings - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Earns "Outperform" Rating from Raymond James - MarketBeat
UBS Group Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock Price - MarketBeat
Leerink Partnrs Forecasts Myriad Genetics Q2 Earnings - MarketBeat
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools - GlobeNewswire
Myriad Genetics Partners With Gabbi To Offer Breast Cancer Risk Assessment & Care Solution - Nasdaq
Myriad Genetics Collaborates with Gabbi to Enhance Breast Cancer Risk Assessment and Care Services - Nasdaq
How Myriad Genetics' New Telehealth Partnership Could Transform Breast Cancer Detection - StockTitan
Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results - Simply Wall St
Myriad Genetics price target lowered to $19 from $27 at Raymond James - MSN
1.12%
1.76%
大文字化:
|
ボリューム (24 時間):